🚀 U.S. Supreme Court Allows Racketeering Lawsuit Against Takeda and Lilly Over Actos
#USSupremeCourt #RacketeeringLawsuit #Takeda #Lilly #Actos #BladderCancer #DiabetesDrug #DeceptivePractices #LegalBattle #PharmaceuticalLawsuit #ConsumerSafety
The U.S. Supreme Court has permitted a multibillion-dollar racketeering lawsuit to proceed against pharmaceutical companies Takeda and Lilly. Bloomberg posted on X, highlighting that the lawsuit accuses the companies of marketing the diabetes drug Actos without revealing its potential link to bladder cancer. This decision marks a significant development in the legal battle surrounding Actos, which has been the subject of numerous lawsuits over its safety. The plaintiffs allege that Takeda and Lilly engaged in deceptive practices by failing to disclose the risks associated with the drug, leading to widespread harm among consumers. The case will now move forward in the legal system, potentially resulting in substantial financial repercussions for the companies involved.#USSupremeCourt #RacketeeringLawsuit #Takeda #Lilly #Actos #BladderCancer #DiabetesDrug #DeceptivePractices #LegalBattle #PharmaceuticalLawsuit #ConsumerSafety
🚀 ImmunityBio Faces FDA Warning Over Bladder Cancer Drug Promotion
#ImmunityBio #FDA #BladderCancer #DrugPromotion #Biotechnology #StockMarket #RegulatoryCompliance #Anktiva
ImmunityBio's shares experienced a significant decline following a warning letter from the U.S. Food and Drug Administration (FDA) regarding the promotion of its bladder cancer drug, Anktiva. Bloomberg posted on X, highlighting that the FDA accused the biotechnology company and its billionaire Executive Chairman, Patrick Soon-Shiong, of false and misleading promotion practices. The FDA's letter emphasized concerns over the promotional materials related to Anktiva, which it deemed to be misleading. This development has raised questions about the company's marketing strategies and compliance with regulatory standards. The impact of the FDA's warning was immediately felt in the stock market, as ImmunityBio's shares dropped sharply. Investors are now closely monitoring the situation to assess the potential implications for the company's future operations and financial performance.#ImmunityBio #FDA #BladderCancer #DrugPromotion #Biotechnology #StockMarket #RegulatoryCompliance #Anktiva